Untitled Document
[an error occurred while processing this directive]
16-31 December 2008  
Untitled Document

IPC Special
Pharma Life
Express Biotech

Open Forum
Editorial Calendar
Media Kit
Contact Us
Network Sites
Express Computer
Express Channel Business
Express Hospitality
Express TravelWorld
feBusiness Traveller
Express Healthcare
Express Textile
Group Sites
Indian Express
Financial Express

[an error occurred while processing this directive]

[an error occurred while processing this directive]

[an error occurred while processing this directive]
Home - Market - Article

Company Watch

Lupin launches Ivabrad

Our News Bureau - Mumbai

Lupin has received Drug Controller General of India (DCGI) approval to launch India’s first selective and specific sinus node I channel inhibitor; Ivabrad (ivabradine). Ivabrad comes from Pinnacle, Lupin’s marketing division for specialty drugs in India. Currently, it is now available in 5 mg and 7.5 mg tablets.

Lupin’s Ivabrad is a new and innovative approach for the treatment of symptomatic chronic stable angina in CAD patients. Stable angina is a common and disabilitating disease that significantly limits the quality of life of patients. It is observed that the traditional heart rate-lowering agents reduce the myocardial contractility, which is harmful when ventricular function is already impaired. As per ORG-IMS estimates, Lupin’s cardiovascular drugs business is among the fastest growing in the Indian market, with sales having grown from about Rs 130 crore, 2006-07 to over Rs 175 crore 2007-08.

Commenting on the launch, Dr Kamal Sharma, Managing Director Lupin, said, “Ivabrad offers doctors and heart patients in India a new and innovative approach for the treatment of symptomatic chronic stable angina in coronary artery disease (CAD) patients, a drug that will have a significant impact on the treatment of cardiovascular diseases in India.”

Sharma commented, “Ivabrad is not only a testament to Lupin’s larger goal of developing and delivering innovative, cost-effective quality drugs for everybody but will also go a long way to further extend and strengthen our goodwill and franchise with cardiologists, in keeping with our market leadership credentials in the cardiovascular space.”

Since the number of existing anti-anginal treatments have limitations and side effects, therefore, there is a need for a drug which not only provides pure heart rate reduction without impairing other cardiac functions but also improves stable angina management.

Ivabrad is a new clinical entity and the first selective sinus node I channel inhibitor which reduces heart rate while maintaining myocardial contractility and atrioventricular (AV) conduction. It is a new alternative indicated in the treatment of chronic stable angina pectoris in patients with normal sinus rhythm.

Shakti P Chakraborty, President, India Region Formulations, Lupin, said, “Statistics today suggest an alarming rise in lifestyle diseases in the next few years. Heart diseases and heart attacks have already assumed epidemic proportions in India over the past decade and treatments such as Ivabrad will go a long way towards controlling these diseases,” Chakraborty added.

According to the World Health Organization (WHO) of all ailments, the spurt in cardiovascular diseases has been the most steep and rapid. While mortality due to cardiovascular diseases has decreased by 60 percent in Japan and Finland, 50 percent in the US and 25 percent in Canada and Australia. It is projected that mortality due to cardiac ailments will in fact increase by 100 percent in India by 2015. The number of people suffering from heart disease and ailments is expected to become 100 million by the year 2010.

Modernisation and changing lifestyles have contributed to the decline in the average age, when a person may suffer from a heart attack from 40 years to 30 years. There has been an overall increase in coronary diseases from six percent to 10 percent in the past decade. The increasing rate of heart diseases amongst the youth is a serious concern as about five percent of the patients who undergo angioplasty and other heart surgeries in the country fall under the age group of 30-35 years.

The ‘Beautiful study’—a large clinical trial undertaken in December 2004 was initiated to evaluate the morbidity-mortality benefits of ivabradine. This involved a total of 10,917 coronary patients with left ventricular dysfunction in 33 countries, and was followed up for a median duration of 19 months and a maximum duration of 35 months. The study revealed that in coronary patients with a heart rate of more than 70 bpm, ivabradine significantly reduces the risk of coronary events by 22 percent, fatal and nonfatal myocardial infarction by 36 percent and coronary revascularisation by 30 percent.

Currently, Lupin commands 5.03 percent of the market share of the same and Lupin’s 34.27 percent year-on-year growth has outperformed the domestic cardiovascular market consistently. The cardiac market in India is estimated to be around Rs 3,600 crore with a growth rate of 18 percent, out of which the market for angina is estimated to be more than Rs 900 crore.

The company has secured global leadership position in anti-TB and cephalosporins and has a significant presence in the areas of cardiovascular (prils and statins), diabetology, asthma and nonsteroidal anti-inflammatory drugs (NSAIDs). The company’s R&D endeavours have resulted in significant progress in its new chemical entity (NCE) programme. The company’s foray into advanced drug delivery systems has resulted in the development of platform technologies that are being used to develop value-added generic pharma.


Untitled Document
Copyright 2001: The Indian Express Limited. All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of The Indian Express Limited. Site managed by BPD.